10-2-6　ⓔ文献

  1. 慶長直人：肺MAC症の疾患感受性．結核，2011; 86: 113–125.

  2. Namkoong H, Kurashima A, et al: Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis, 2016; 22: 1116–1117.

  3. Morimoto K, Hasegawa N, et al: A laboratory–based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc, 2017; 14: 49–56.

  4. 日本結核病学会編：非結核性抗酸菌症診療マニュアル，医学書院，2015.

  5. 日本結核病学会非結核性抗酸菌症対策委員会，日本呼吸器学会感染症・結核学術部会：肺非結核性抗酸菌症診断に関する指針―2008年．結核，2008; 83: 525–526.

  6. 森本耕三：肺Mycobacterium avium complex症における治療期間の妥当性―臨床データから見た妥当な期間とは．結核，2012; 87: 443–446.

  7. Griffith DE, Akamit T, et al: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007; 175: 367–416.

  8. Haworth CS, Banks J, et al: British Thoracic Society guidelines for the management of non–tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017; 72: ii1–ii64.

  9. 日本結核病学会非結核性抗酸菌症対策委員会：肺非結核性抗酸菌症に対する外科治療の指針．結核，2008; 83: 527–528.

  10. Morimoto K, Iwai K, et al: A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc, 2014; 11: 1–8.

  11. Jhun BW, Moon SM, et al: Prognostic factors associated with long–term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15–year follow–up study. Eur Respir J, 2020; 55: pii: 1900798.

  12. 中川　拓，小川賢二：非結核性抗酸菌症．日本内科学会雑誌，2010; 99: 2709–2714.